Rhinophyma Treated with Fractional CO2 Laser Resurfacing in a Woman of Color
JDD authors Samuel S. Kassirer BA, Robert H. Gotkin MD, and Deborah S. Sarnoff MD present the first reported case of rhinophyma in a 62-year-old Fitzpatrick V female patient who was successfully treated with one session of fractional CO2 laser resurfacing. This case highlights the successful use of the fractional CO2 laser to treat rhinophyma in darker skin types (Fitzpatrick IV–VI) and undersco …
Suncare Sundays: Skin Cancer Facts
melanomaEvery day in the US more than 9500 people will be diagnosed with skin cancer. More people are diagnosed with skin cancer each year in the U.S than all other cancers combined. The earlier skin cancer is detected and treated, the better chance of a cure. 1 in 5 Americans will develop skin cancer by the age of 70. More than 2 people die of skin cancer in the U.S. every hour. Having 5 …
melanoma
Skin of Color Update 2021: Bigger & Better Than Ever!
Skin of Color UpdateSkin of Color Update, the largest medical education event focused on the dermatologic treatment of patients with skin of color, is expanding in 2021 with an additional half day of programming and pre-conference symposium. The event will be held virtually September 10-12 with the symposium on August 3. “The expanded program will allow us to address even more topics and provide more in-depth co …
Skin of Color Update
Dermatology KOLs on Becoming a Go-To Media Expert
Media Expert in DermatologyDermatology KOLs Adam Friedman, MD and Joel L. Cohen, MD, and Heather Onorati, former dermatology magazine editor and managing editor for Pathogens and Immunity journal, share their expert advice on becoming a go-to media expert in the dermatology When Adam Friedman, MD, began his dermatology career, he made the most of every media opportunity that came his way. He sent reporters scientific pap …
Media Expert in Dermatology
Hand Foot Skin Reaction Associated With Palbociclib
PalbociclibINTRODUCTION Palbociclib is one of three new small-molecule inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6) approved for use in the treatment of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (Her2-) advanced or metastatic breast cancer. CDK4/6 inhibitors have a good overall safety profile but reported side effects include cytopenias, diarrhea, QTc pr …
Palbociclib